
Opinion|Videos|April 14, 2025
BESPOKE: ctDNA Clearance During and After ACT
Author(s)John L. Marshall, MD, Mark Lewis, MD
Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes.
Advertisement
Episodes in this series

Advertisement
Related to this article

Data from the phase 1/2 ALKOVE-1 trial support the FDA approval of neladalkib in this non–small cell lung cancer population.

After an FDA Type C meeting, registrational trials of the DLL3-targeting ADC IDE849 in pretreated neuroendocrine carcinomas are set to begin by year-end.

Alembic’s binimetinib 15-mg and 45-mg tablets, given with encorafenib, received final FDA approval for BRAF-mutant melanoma and NSCLC.

The American Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which may help advance research and care.

At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.

The FDA granted breakthrough therapy designation to 64Cu-SAR-bisPSMA for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer.

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer
2
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
3
Darovasertib Plus Crizotinib Yields 21.1-Month OS in First-Line Uveal Melanoma
4
Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?
5
